ଟାଜେମେଟୋଷ୍ଟାଟ

ଟାଜେମେଟୋଷ୍ଟାଟ
Clinical data
Trade names	Tazverik, others
Synonyms	EPZ-6438
AHFS/Drugs.com	monograph
MedlinePlus	a620018
data	US DailyMed: Tazemetostat;
Routes of; administration	By mouth
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name N-[(4,6-Dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-[ethyl(oxan-4-yl)amino]-2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]benzamide;
Chemical and physical data
Formula	C34H44N4O4
Molar mass	୫୭୨.୭୫ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCN(C1CCOCC1)C2=CC(=CC(=C2C)C(=O)NCC3=C(C=C(NC3=O)C)C)C4=CC=C(C=C4)CN5CCOCC5;
	InChI InChI=1S/C34H44N4O4/c1-5-38(29-10-14-41-15-11-29)32-20-28(27-8-6-26(7-9-27)22-37-12-16-42-17-13-37)19-30(25(32)4)33(39)35-21-31-23(2)18-24(3)36-34(31)40/h6-9,18-20,29H,5,10-17,21-22H2,1-4H3,(H,35,39)(H,36,40); Key:NSQSAUGJQHDYNO-UHFFFAOYSA-N;

ଟାଜେମେଟୋଷ୍ଟାଟ (ଇଂରାଜୀ ଭାଷାରେ Tazemetostat), ଟାଜଭେରିକ ଏହାର ବିକ୍ରୟ ନାମ, ହେଉଛି ଏକ ଔଷଧ ଯାହା ଅସ୍ତ୍ରୋପଚାର ସାହାଯ୍ୟରେ ବାହାର କରିହେଉନଥିବା ଏବଂ ଅନ୍ୟାନ୍ୟ ଚିକିତ୍ସାରେ ବିଫଳ ହେଉଥିବା ନନ୍-ହଜକିନ୍ସ ଲିମ୍ଫୋମା ରୋଗମାନଙ୍କରେ ଦିଆଯାଏ ।^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ ।^[୧]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଯନ୍ତ୍ରଣା, ଥକାପଣ, ଅଇ, ଅରୁଚି, ବାନ୍ତି ଏବଂ କୋଷ୍ଠକାଠିନ୍ୟ ହୋଇପାରେ ।^[୧] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଟି-ସେଲ୍ ଲିମ୍ଫୋବ୍ଲାଷ୍ଟିକ ଲିମ୍ଫୋମା, ମାୟେଲୋଡିସପ୍ଲାଷ୍ଟିକ୍ ସିଣ୍ଡ୍ରୋମ ଏବଂ ଆକ୍ୟୁଟ୍ ମାଇଲୋଏଡ୍ ଲ୍ୟୁକେମିଆ ସହିତ ଦ୍ୱିତୀୟକ କର୍କଟ ହୋଇପାରେ ।^[୨] ଏହା ଇଜେଡଏଚ୨ (EZH2)ର କାର୍ଯ୍ୟକଳାପକୁ ଅବରୋଧ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।^[୩]

୨୦୨୦ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା କ୍ଷେତ୍ରରେ ବ୍ୟବହାର ପାଇଁ ଟାଜେମେଟୋଷ୍ଟାଟ ଅନୁମୋଦିତ ହୋଇଥିଲା ।^[୧] ୨୦୨୧ ସୁଦ୍ଧା ୟୁରୋପରେ ସମ୍ପୂର୍ଣ୍ଣ ଅନୁମୋଦନ ହୋଇନାହିଁ; ଯଦିଓ ଏକ ଅନାଥ ନାମକରଣ ଦିଆଯାଇଛି ।^[୪] ^[୫] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ୨୦୨୧ ସୁଦ୍ଧା ମାସକୁ ଏହା ପିଛା ପ୍ରାୟ ୧୭,୩୦୦ ଡଲାର ଖର୍ଚ୍ଚ ହୋଇଥାଏ ।^[୬]

ଆଧାର

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Tazemetostat Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 July 2021. Retrieved 24 September 2021.
↑ "FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer" (Press release). 23 January 2020. Archived from the original on 25 December 2020. Retrieved 23 January 2020.
↑ Lue JK, Amengual JE (October 2018). "Emerging EZH2 Inhibitors and Their Application in Lymphoma". Curr Hematol Malig Rep. 13 (5): 369–382. doi:10.1007/s11899-018-0466-6. PMID 30112706.
↑ "Tazemetostat". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 24 May 2021. Retrieved 24 September 2021.
↑ "EU/3/18/2004: Orphan designation for the treatment of diffuse large B-cell lymphoma". Archived from the original on 24 September 2021. Retrieved 24 September 2021.
↑ "Tazverik Prices, Coupons and Patient Assistance Programs". Retrieved 24 September 2021.

[AHFS2021-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ "Tazemetostat Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 11 July 2021. Retrieved 24 September 2021.

[FDA2020PR-2] "FDA approves first treatment option specifically for patients with epithelioid sarcoma, a rare soft tissue cancer" (Press release). 23 January 2020. Archived from the original on 25 December 2020. Retrieved 23 January 2020.

[3] Lue JK, Amengual JE (October 2018). "Emerging EZH2 Inhibitors and Their Application in Lymphoma". Curr Hematol Malig Rep. 13 (5): 369–382. doi:10.1007/s11899-018-0466-6. PMID 30112706.

[SPS2021-4] "Tazemetostat". SPS - Specialist Pharmacy Service. 17 September 2019. Archived from the original on 24 May 2021. Retrieved 24 September 2021.

[5] "EU/3/18/2004: Orphan designation for the treatment of diffuse large B-cell lymphoma". Archived from the original on 24 September 2021. Retrieved 24 September 2021.

[6] "Tazverik Prices, Coupons and Patient Assistance Programs". Retrieved 24 September 2021.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]